SCHEMBL19769172

SCHEMBL19769172

CC(=O)N1CCN(c2cncc3sc(C(N)=O)cc23)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ICAM1 P05362 16/20 0.51
SELE P16581 15/20 0.51
VCAM1 P19320 5/20 0.51
PIM1 P11309 4/20 0.46
KDR P35968 4/20 0.46
GSK3A P49840 4/20 0.46
RPS6KA3 P51812 4/20 0.46
LIMK1 P53667 4/20 0.46
CDK5 Q00535 4/20 0.46
DAPK3 O43293 3/20 0.46
PRKACA P17612 3/20 0.46
MAPK8 P45983 3/20 0.46
GSK3B P49841 3/20 0.46
CHEK2 O96017 3/20 0.46
CDK1 P06493 3/20 0.46
FGFR3 P22607 3/20 0.46
CDK2 P24941 3/20 0.46
MAPK9 P45984 3/20 0.46
CSNK1D P48730 3/20 0.46
CSNK2A1 P68400 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19769117 0.85 ICAM1 (0.56) ICAM1SELEVCAM1PIM1KDR
SCHEMBL7053106 0.82 ICAM1 (0.55) ICAM1SELEVCAM1PIM1KDR
SCHEMBL19769134 0.77 ICAM1 (0.46) ICAM1SELEVCAM1PIM1KDR
SCHEMBL19769189 0.75 CDK8 (0.43) GSK3ACSNK1DCDK8CSNK1A1
SCHEMBL19780460 0.74 ICAM1 (0.54) ICAM1SELEVCAM1PIM1KDR
SCHEMBL19780462 0.74 ICAM1 (0.54) ICAM1SELEVCAM1PIM1KDR
SCHEMBL19780864 0.74 ICAM1 (0.46) ICAM1SELEVCAM1PIM1KDR
SCHEMBL12115078 0.73 CDK8 (0.54) CHEK1CDK8
SCHEMBL15518133 0.71 ICAM1 (0.67) ICAM1SELEVCAM1PIM1KDR
SCHEMBL17996837 0.70 ALDH1A1 (0.50) KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10154992-B2 Compounds and methods for treating HIV infection THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-12-18 US disclosed
US-20180015077-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTION NAKAMURA, ROBERT 2018-01-18 US disclosed
US-20180015077-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTION NAKAMURA, ROBERT 2018-01-18 US disclosed
US-20180015077-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTION NAKAMURA, ROBERT 2018-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10154992-B2 Compounds and methods for treating HIV infection CD4, CCR5, MMP8 ICAM1 65/4885SELE 751/4885VCAM1 422/4885
US-20180015077-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTION CD4, CCR5, MMP8 ICAM1 65/4885SELE 751/4885VCAM1 422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.